Biohaven's Opakalim Shows Strong Seizure Control in Epilepsy Data, Prolonging Time to Second Seizure to 141 Days
Summary
Biohaven announced positive new clinical data for its drug Opakalim in epilepsy, showing it significantly prolonged the median time to a second seizure to 141 days, compared to 47 days for placebo. This data also highlighted a favorable tolerability profile. This is a material positive development for Opakalim, especially following its prior late-stage clinical trial failures in MDD and bipolar disorder as disclosed in the March 2, 2026 10-K. Investors will now watch for top-line Phase 2/3 results in refractory focal epilepsy, expected in the second half of 2026.
At the time of this announcement, BHVN was trading at $9.49 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $7.48 to $18.57. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.